A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Inclusion Criteria:

   - Age >/= 18 years

   - ECOG score of 0-1

   - One of the following histologically-documented hematologic malignancies for which no
   effective standard therapy exists: indolent non Hodgkin's lymphoma (NHL), follicular
   lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), or
   chronic lymphocytic leukemia (CLL)

   - At least one site of disease that, as seen on CT scan, is > 1.5 cm in the greatest
   transverse diameter or > 1.0 cm in short axis diameter (except for patients with CLL)

   - An available tumor specimen

   - Adequate hematologic and organ function

   - For female patients of childbearing potential and male patients with partners of
   childbearing potential, use of effective contraceptive(s) as defined by protocol for
   the duration of the study

Exclusion Criteria:

   - Life expectancy < 12 weeks

   - < 3 weeks since the last anti-tumor therapy, including chemotherapy, biologic,
   experimental, hormonal or radiotherapy (with the exception of leuprolide or similar
   medications for prostate cancer)

   - Recent major surgical procedure or traumatic injury, or unhealed incisions or wounds

   - Active infection requiring IV antibiotics

   - Clinically significant history of liver disease, including viral or other hepatitis,
   current alcohol abuse, or cirrhosis.

   - Primary CNS malignancy or untreated/active CNS metastases (progressing or requiring
   anticonvulsants or corticosteroids for symptomatic control)

   - History of other malignancy within 5 years prior to screening, except for
   appropriately treated carcinoma in situ of the cervix, non-melanoma skin cancer, Stage
   I uterine cancer, or other cancers with a similar outcome

   - Cardiovascular dysfunction, including ventricular dysrhythmias or risk factors for
   ventricular dysrhythmias

   - Pregnancy, or lactation

   - Any other diseases that contraindicates the use of an investigational drug or that may
   affect the interpretation of the results or render the patient at high risk from
   treatment complications